- Home
- TENX
as 05-13-2024 4:00pm EST
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | CHAPEL HILL |
| Market Cap: | 7.0M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 110.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -31.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.45 - $61.20 | Next Earning Date: | 05-21-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Tenax Therapeutics Inc. News
TENX Breaking Stock News: Dive into TENX Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
GlobeNewswire
a month ago
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Zacks Small Cap Research
a month ago
TENX: 2023 Financial Results
GlobeNewswire
2 months ago
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
GlobeNewswire
2 months ago
Tenax Therapeutics to Present at the 36th Annual Roth Conference
GlobeNewswire
2 months ago
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
GlobeNewswire
3 months ago
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Zacks Small Cap Research
3 months ago